Judit Kocsis

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023 · 279 citations · Full text

Oncology, Gastrointestinal Oncology, Colorectal Cancer +6

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

Tamas Hickish, Thierry André, Lucjan Wyrwicz et al. · The Lancet Oncology · 2017 · 153 citations

Novel Antibody Treatment, Medicine, Immunology +7